keyword
MENU ▼
Read by QxMD icon Read
search

Glenn Chertow

keyword
https://www.readbyqxmd.com/read/29762046/effects-of-calcimimetics-on-long-term-outcomes-in-dialysis-patients-literature-review-and-bayesian-meta-analysis
#1
Greta Lozano-Ortega, Nathalie Waser, Mark E Bensink, Sarah Goring, Heather Bennett, Geoffrey A Block, Glenn M Chertow, Marie-Louise Trotman, Kerry Cooper, Adrian R Levy, Vasily Belozeroff
AIM: Randomized controlled trials (RCTs) with clinical outcomes are considered the gold standard for regulatory approval. However, by design they are only able to answer a small number of clinical questions. Other high-quality studies are required for clinical decision-making. The EVOLVE was the largest RCT, evaluating the effects of cinacalcet on clinical outcomes among adult patients receiving maintenance dialysis suffering from secondary hyperparathyroidism. While the EVOLVE trial did not reach its primary end point, imbalance in subjects' age at randomization and discontinuation rates are two of the reasons that the lack of mortality benefit is in question...
May 15, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29685860/intensive-systolic-blood-pressure-control-and-incident-chronic-kidney-disease-in-people-with-and-without-diabetes-mellitus-secondary-analyses-of-two-randomised-controlled-trials
#2
Srinivasan Beddhu, Tom Greene, Robert Boucher, William C Cushman, Guo Wei, Gregory Stoddard, Joachim H Ix, Michel Chonchol, Holly Kramer, Alfred K Cheung, Paul L Kimmel, Paul K Whelton, Glenn M Chertow
BACKGROUND: Guidelines, including the 2017 American College of Cardiology and American Heart Association blood pressure guideline, recommend tighter control of systolic blood pressure in people with type 2 diabetes. However, it is unclear whether intensive lowering of systolic blood pressure increases the incidence of chronic kidney disease in this population. We aimed to compare the effects of intensive systolic blood pressure control on incident chronic kidney disease in people with and without type 2 diabetes...
April 20, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29672740/effects-of-vadadustat-on-hemoglobin-concentrations-in-patients-receiving-hemodialysis-previously-treated-with-erythropoiesis-stimulating-agents
#3
Volker H Haase, Glenn M Chertow, Geoffrey A Block, Pablo E Pergola, Emil M deGoma, Zeeshan Khawaja, Amit Sharma, Bradley J Maroni, Peter A McCullough
Background: Vadadustat, an inhibitor of hypoxia-inducible factor prolyl-4-hydroxylase domain dioxygenases, is an oral investigational agent in development for the treatment of anemia secondary to chronic kidney disease. Methods: In this open-label Phase 2 trial, vadadustat was evaluated in 94 subjects receiving hemodialysis, previously maintained on epoetin alfa. Subjects were sequentially assigned to one of three vadadustat dose cohorts by starting dose: 300 mg once daily (QD), 450 mg QD or 450 mg thrice weekly (TIW)...
April 16, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29629191/chronic-kidney-disease-care-models-in-low-and-middle-income-countries-a-systematic-review
#4
John W Stanifer, Megan Von Isenburg, Glenn M Chertow, Shuchi Anand
Introduction: The number of persons with chronic kidney disease (CKD) living in low- and middle-income countries (LMIC) is increasing rapidly; yet systems built to care for them have received little attention. In order to inform the development of scalable CKD care models, we conducted a systematic review to characterise existing CKD care models in LMICs. Methods: We searched PubMed, Embase and WHO Global Health Library databases for published reports of CKD care models from LMICs between January 2000 and 31 October 2017...
2018: BMJ Global Health
https://www.readbyqxmd.com/read/29617976/the-effects-of-tenapanor-on-serum-fibroblast-growth-factor-23-in-patients-receiving-hemodialysis-with-hyperphosphatemia
#5
Geoffrey A Block, David P Rosenbaum, Andrew Yan, Peter J Greasley, Glenn M Chertow, Myles Wolf
Background: Elevated serum fibroblast growth factor 23 (FGF23) is strongly associated with cardiovascular risk and mortality. Tenapanor, an inhibitor of gastrointestinal sodium/hydrogen exchanger isoform 3, decreased serum phosphate in a randomized, double-blind, placebo-controlled Phase 2 trial (ClinicalTrials.gov identifier NCT02081534) of patients receiving hemodialysis with hyperphosphatemia. Here, we report a secondary analysis of effects on serum FGF23 during that study. Methods: After 1-3 weeks of washout of phosphate binders, 162 patients were randomized to receive 4 weeks of treatment with placebo or one of six tenapanor regimens (3 or 30 mg once daily, or 1, 3, 10 or 30 mg twice daily)...
April 3, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29601836/unplanned-emergency-department-visits-and-hospital-admissions-following-ureteroscopy-do-ureteral-stents-make-a-difference
#6
Harsha R Mittakanti, Simon L Conti, Alan C Pao, Glenn M Chertow, Joseph C Liao, John T Leppert, Christopher S Elliott
OBJECTIVE: The comparative effectiveness of ureteral stents placed during ureteroscopy for urinary stone disease is widely debated. We sought to evaluate unplanned medical visits within the early post-operative period after ureteroscopy in patients with and without ureteral stent placement. MATERIALS AND METHODS: We identified all ureteroscopic procedures for urinary stone disease in the California Office of Statewide Health Planning and Development (OSHPD) database from 2010-2012...
March 27, 2018: Urology
https://www.readbyqxmd.com/read/29584720/cost-effectiveness-of-multidisciplinary-care-in-mild-to-moderate-chronic-kidney-disease-in-the-united-states-a-modeling-study
#7
Eugene Lin, Glenn M Chertow, Brandon Yan, Elizabeth Malcolm, Jeremy D Goldhaber-Fiebert
BACKGROUND: Multidisciplinary care (MDC) programs have been proposed as a way to alleviate the cost and morbidity associated with chronic kidney disease (CKD) in the US. METHODS AND FINDINGS: We assessed the cost-effectiveness of a theoretical Medicare-based MDC program for CKD compared to usual CKD care in Medicare beneficiaries with stage 3 and 4 CKD between 45 and 84 years old in the US. The program used nephrologists, advanced practitioners, educators, dieticians, and social workers...
March 2018: PLoS Medicine
https://www.readbyqxmd.com/read/29554056/comparing-simultaneous-liver-kidney-transplant-strategies-a-modified-cost-effectiveness-analysis
#8
Xingxing S Cheng, W Ray Kim, Jane C Tan, Glenn M Chertow, Jeremy Goldhaber-Fiebert
BACKGROUND: The proportion of patients with kidney failure at time of liver transplantation is at an historic high in the United States. The optimal timing of kidney transplantation with respect to the liver transplant is unknown. METHODS: We used a modified cost-effectiveness analysis to compare four strategies: the old system ("pre-OPTN"), the new Organ Procurement Transplant Network (OPTN) system since August 10, 2017 ("OPTN"), and two strategies which restrict simultaneous liver-kidney transplants ("safety net" and "stringent")...
March 16, 2018: Transplantation
https://www.readbyqxmd.com/read/29525393/incidence-predictors-and-therapeutic-consequences-of-hypocalcemia-in-patients-treated-with-cinacalcet-in-the-evolve-trial
#9
Jürgen Floege, Kate Tsirtsonis, Jan Iles, Tilman B Drueke, Glenn M Chertow, Patrick Parfrey
The calcimimetic cinacalcet is used to treat secondary hyperparathyroidism in patients receiving dialysis, and asymptomatic hypocalcemia is often observed following its initiation. Here we investigated the incidence, predictors and therapeutic consequences of hypocalcemia by a post hoc analysis of the randomized, double-blind, placebo-controlled EValuation Of Cinacalcet Hydrochloride Therapy to Lower CardioVascular Events (EVOLVE) trial. Hypocalcemia was classified as mild (total serum calcium 8.0-8.39 mg/dL), moderate (7...
March 7, 2018: Kidney International
https://www.readbyqxmd.com/read/29496260/hyperuricemia-acute-and-chronic-kidney-disease-hypertension-and-cardiovascular-disease-report-of-a-scientific-workshop-organized-by-the-national-kidney-foundation
#10
Richard J Johnson, George L Bakris, Claudio Borghi, Michel B Chonchol, David Feldman, Miguel A Lanaspa, Tony R Merriman, Orson W Moe, David B Mount, Laura Gabriella Sanchez Lozada, Eli Stahl, Daniel E Weiner, Glenn M Chertow
Urate is a cause of gout, kidney stones, and acute kidney injury from tumor lysis syndrome, but its relationship to kidney disease, cardiovascular disease, and diabetes remains controversial. A scientific workshop organized by the National Kidney Foundation was held in September 2016 to review current evidence. Cell culture studies and animal models suggest that elevated serum urate concentrations can contribute to kidney disease, hypertension, and metabolic syndrome. Epidemiologic evidence also supports elevated serum urate concentrations as a risk factor for the development of kidney disease, hypertension, and diabetes, but differences in methodologies and inpacts on serum urate concentrations by even subtle changes in kidney function render conclusions uncertain...
February 26, 2018: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/29475561/updated-guidelines-for-the-diagnosis-and-management-of-high-blood-pressure-implications-for-clinical-practice-in-nephrology
#11
Christina M Wyatt, Glenn M Chertow
No abstract text is available yet for this article.
April 2018: Kidney International
https://www.readbyqxmd.com/read/29468675/market-competition-and-health-outcomes-in-hemodialysis
#12
Kevin F Erickson, Yuanchao Zheng, Vivian Ho, Wolfgang C Winkelmayer, Jay Bhattacharya, Glenn M Chertow
OBJECTIVE: To examine whether market competition is associated with improved health outcomes in hemodialysis. DATA SOURCES: Secondary analysis of data from a national dialysis registry between 2001 and 2011. STUDY DESIGN: We conducted one- and two-part linear regression models, using each hospital service area (HSA) as its own control, to examine the independent associations among market concentration and health outcomes. DATA COLLECTION: We selected cohorts of patients receiving in-center hemodialysis in the United States at the start of each calendar year...
February 22, 2018: Health Services Research
https://www.readbyqxmd.com/read/29417614/comparative-safety-of-intravenous-ferumoxytol-versus-ferric-carboxymaltose-in-iron-deficiency-anemia-a-randomized-trial
#13
N Franklin Adkinson, William E Strauss, Iain C Macdougall, Kristine E Bernard, Michael Auerbach, Robert F Kaper, Glenn M Chertow, Julie S Krop
Few trials have examined rates of hypersensitivity reactions (HSRs) with intravenous iron formulations used to treat iron deficiency anemia (IDA). This randomized, multicenter, double-blind clinical trial compared the safety, and efficacy of ferumoxytol versus ferric carboxymaltose (FCM), focusing on rates of HSRs and hypotension as the primary end point. Patients with IDA of any etiology in whom oral iron was unsatisfactory or intolerable received ferumoxytol (n = 997) or FCM (n = 1000) intravenously over ≥15 minutes on days 1 and 8 or 9 for total respective doses of 1...
May 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29402767/bardoxolone-methyl-improves-kidney-function-in-patients-with-chronic-kidney-disease-stage-4-and-type-2-diabetes-post-hoc-analyses-from-bardoxolone-methyl-evaluation-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-study
#14
Melanie P Chin, George L Bakris, Geoffrey A Block, Glenn M Chertow, Angie Goldsberry, Lesley A Inker, Hiddo J L Heerspink, Megan O'Grady, Pablo E Pergola, Christoph Wanner, David G Warnock, Colin J Meyer
BACKGROUND: Increases in measured inulin clearance, measured creatinine clearance, and estimated glomerular filtration rate (eGFR) have been observed with bardoxolone methyl in 7 studies enrolling approximately 2,600 patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The largest of these studies was Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), a multinational, randomized, double-blind, placebo-controlled phase 3 trial which enrolled patients with T2D and CKD stage 4...
2018: American Journal of Nephrology
https://www.readbyqxmd.com/read/29361496/associations-of-lipoproteins-with-cardiovascular-and-infection-related-outcomes-in-patients-receiving-hemodialysis
#15
George A Kaysen, Barbara Grimes, Lorien S Dalrymple, Glenn M Chertow, Julie H Ishida, Cynthia Delgado, Mark Segal, Janet Chiang, Tjien Dwyer, Kirsten L Johansen
BACKGROUND: In hemodialysis (HD) patients, higher lipid levels are associated with lower mortality. Lipid-lowering therapy does not reduce all-cause mortality or cardiovascular (CV) mortality. Lipoproteins play a role in the innate immune system. Our objective was to determine whether protection from infection might counterbalance adverse CV outcomes associated with lipoproteins. METHODS: We examined associations between serum apolipoprotein (Apo) A1, B, C2, C3, high-density lipoprotein and low-density lipoprotein (LDL) cholesterol and triglyceride levels and infectious mortality or hospitalization, CV mortality or hospitalization, and all-cause mortality in 433 prevalent HD patients...
March 2018: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29242248/causes-of-death-after-a-hospitalization-with-aki
#16
Samuel A Silver, Ziv Harel, Eric McArthur, Danielle M Nash, Rey Acedillo, Abhijat Kitchlu, Amit X Garg, Glenn M Chertow, Chaim M Bell, Ron Wald
Mortality after AKI is high, but the causes of death are not well described. To better understand causes of death in patients after a hospitalization with AKI and to determine patient and hospital factors associated with mortality, we conducted a population-based study of residents in Ontario, Canada, who survived a hospitalization with AKI from 2003 to 2013. Using linked administrative databases, we categorized cause of death in the year after hospital discharge as cardiovascular, cancer, infection-related, or other...
March 2018: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/29203473/perioperative-thr-184-and-aki-after-cardiac-surgery
#17
Jonathan Himmelfarb, Glenn M Chertow, Peter A McCullough, Thierry Mesana, Andrew D Shaw, Thoralf M Sundt, Craig Brown, David Cortville, François Dagenais, Benoit de Varennes, Manuel Fontes, Jerome Rossert, Jean-Claude Tardif
AKI after cardiac surgery is associated with mortality, prolonged hospital length of stay, use of dialysis, and subsequent CKD. We evaluated the effects of THR-184, a bone morphogenetic protein-7 agonist, in patients at high risk for AKI after cardiac surgery. We conducted a randomized, double-blind, placebo-controlled, multidose comparison of the safety and efficacy of perioperative THR-184 using a two-stage seamless adaptive design in 452 patients between 18 and 85 years of age who were scheduled for nonemergent cardiac surgery requiring cardiopulmonary bypass and had recognized risk factors for AKI...
February 2018: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/29201600/donation-not-disease-a-multiple-hit-hypothesis-on-development-of-post-donation-kidney-disease
#18
REVIEW
Xingxing S Cheng, Richard J Glassock, Krista L Lentine, Glenn M Chertow, Jane C Tan
Purpose of Review: The risks following living kidney donation has been the subject of rigorous investigation in the past several decades. How to utilize the burgeoning new knowledge base to better the risk assessment, education, and health maintenance of donors is unclear. We review the physiologic and epidemiologic evidences on the post-donation state and submit a multiple-hit hypothesis to reconcile the finite elevation in risk of kidney disease after donation with the benign course of most kidney donors...
2017: Current Transplantation Reports
https://www.readbyqxmd.com/read/29186198/safety-and-efficacy-of-ferric-citrate-in-patients-with-nondialysis-dependent-chronic-kidney-disease
#19
RANDOMIZED CONTROLLED TRIAL
Glenn M Chertow, Geoffrey A Block, John F Neylan, Pablo E Pergola, Katrin Uhlig, Steven Fishbane
Two randomized, placebo-controlled trials conducted in patients with nondialysis-dependent (NDD) chronic kidney disease (CKD), iron deficiency anemia, and normal or elevated serum phosphorus demonstrated that ferric citrate (FC) significantly increased hemoglobin and decreased serum phosphate concentrations. Pooling these trial results could provide a more robust evaluation of the safety and efficacy of FC in this population. We pooled results of a phase 2 (n = 149) and 3 trial (n = 233) of patients randomized and treated for up to 12 and 16 weeks, respectively...
2017: PloS One
https://www.readbyqxmd.com/read/29162340/effects-of-intensive-blood-pressure-treatment-on-acute-kidney-injury-events-in-the-systolic-blood-pressure-intervention-trial-sprint
#20
Michael V Rocco, Kaycee M Sink, Laura C Lovato, Dawn F Wolfgram, Thomas B Wiegmann, Barry M Wall, Kausik Umanath, Frederic Rahbari-Oskoui, Anna C Porter, Roberto Pisoni, Cora E Lewis, Julia B Lewis, James P Lash, Lois A Katz, Amret T Hawfield, William E Haley, Barry I Freedman, Jamie P Dwyer, Paul E Drawz, Mirela Dobre, Alfred K Cheung, Ruth C Campbell, Udayan Bhatt, Srinivasan Beddhu, Paul L Kimmel, David M Reboussin, Glenn M Chertow
BACKGROUND: Treating to a lower blood pressure (BP) may increase acute kidney injury (AKI) events. STUDY DESIGN: Data for AKI resulting in or during hospitalization or emergency department visits were collected as part of the serious adverse events reporting process of the Systolic Blood Pressure Intervention Trial (SPRINT). SETTING & PARTICIPANTS: 9,361 participants 50 years or older with 1 or more risk factors for cardiovascular disease...
March 2018: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
keyword
keyword
61939
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"